↓ Skip to main content

Dove Medical Press

Article Metrics

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats

Overview of attention for article published in Drug Design, Development and Therapy, November 2012
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
25 Mendeley
Title
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
Published in
Drug Design, Development and Therapy, November 2012
DOI 10.2147/dddt.s38008
Pubmed ID
Authors

Weien Yuan, Xinxin Yang, Yinghui Chen, Xiaoyun Hong, Na Wu, Lu Song, Zhenguo Liu

Abstract

Levodopa is the gold standard in the treatment of Parkinson's disease (PD). However, long-term levodopa replacement therapy is accompanied by abnormal involuntary movements (AIMs), known as levodopa-induced dyskinesia (LID). Until now, the precise mechanisms of LID were only partially understood. Previous studies have shown that continuous dopamine stimulation was helpful in reducing the expression of LID. In addition to dopamine D1 receptor, glutamatergic receptors such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also contribute to the expression of LID. The current authors have previously reported that levodopa/benserazide-loaded microspheres could ameliorate the expression of LID by reducing the protein kinase A signaling pathway in dyskinetic rats. However, whether AMPA receptor is involved in the mechanism by which levodopa/benserazide-loaded microspheres ameliorate the expression of LID in dyskinetic rats was unknown.

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 24%
Student > Master 4 16%
Researcher 3 12%
Student > Doctoral Student 2 8%
Professor > Associate Professor 2 8%
Other 5 20%
Unknown 3 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 9 36%
Biochemistry, Genetics and Molecular Biology 2 8%
Neuroscience 2 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Arts and Humanities 1 4%
Other 4 16%
Unknown 6 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2012.
All research outputs
#2,900,765
of 3,635,018 outputs
Outputs from Drug Design, Development and Therapy
#265
of 312 outputs
Outputs of similar age
#218,674
of 275,193 outputs
Outputs of similar age from Drug Design, Development and Therapy
#18
of 22 outputs
Altmetric has tracked 3,635,018 research outputs across all sources so far. This one is in the 2nd percentile – i.e., 2% of other outputs scored the same or lower than it.
So far Altmetric has tracked 312 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,193 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.